US Stock MarketDetailed Quotes
CHRS Coherus BioSciences
- 1.700
- +0.060+3.66%
Close Jul 22 16:00 ET
- 1.710
- +0.010+0.59%
Post 17:46 ET
195.03MMarket Cap-2297P/E (TTM)
1.715High1.580Low1.95MVolume1.670Open1.640Pre Close3.24MTurnover2.02%Turnover RatioLossP/E (Static)114.73MShares5.46552wk High-2.38P/B164.21MFloat Cap1.25052wk Low--Dividend TTM96.59MShs Float38.100Historical High--Div YieldTTM8.23%Amplitude1.250Historical Low1.661Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Coherus BioSciences Stock Forum
Coherus BioSciences Inc - Apotex Agreed to Pay to Company an Upfront Payment of $6.25 Mln United States Dollars under license agreement
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
HODL to the Moon.
Chs-114 Shown to Have Acceptable Safety Profile With No Dose-Limiting Toxicities in Heavily Pretreated Patients With Solid Tumors
NEWS
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Coherus BioSciences announced preliminary Phase 1 results for CHS-114, an anti-CCR8 antibody, at the 2024 ASCO Annual Meeting. CHS-114 exhibited an acceptable safety profile with no dose-limiting toxicities in heavily pretreated patients with solid tumors. Sele...
NEWS
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
Coherus BioSciences, Inc. announced a clinical collaboration with the Cancer Research Institute (CRI) to explore a combination of LOQTORZI (toripalimab-tpzi) with ENB-003 for the treatment of ovarian cancer. The iPROC platform study aims to investigate the ...
Dow Jones· 5 mins ago
No comment yet